BIRMINGHAM, ALA.--(BUSINESS WIRE)--
CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, announced today that its molecular diagnostics laboratory has received College of American Pathologists (CAP) accreditation based on a recent on-site inspection as part of CAP’s Accreditation Programs. The CAP accreditation – and the Clinical Laboratory Improvement Amendments (CLIA) certification that CIRCULOGENE achieved in 2015 – are internationally recognized credentials awarded to laboratories complying with the most comprehensive, rigorous and scientifically-endorsed standards of laboratory practice.
“This CAP accreditation milestone is a testament to the high-quality scientific standards that our laboratory strives for in pursuit of molecular diagnostics testing excellence and better patient care,” said CIRCULOGENE Chief Scientific Officer Chen-Hsiung Yeh, Ph.D. “We’ll continue to advance precision medicine through our highly accurate, automated and scalable cell-free DNA and RNA technology to help clinicians fight an increasingly broad range of cancers.”
Bharati Jhaveri, M.D., F.C.A.P., chair of the CAP’s Council on Accreditation, recognized CIRCULOGENE on its achievement.
“The CAP congratulates CIRCULOGENE on its recent CAP Accreditation,” said Jhaveri. “CIRCULOGENE demonstrates leadership, innovation and a passionate commitment to standards of excellence while providing the highest quality services, ultimately benefiting patients.”
CIRCULOGENE’s proprietary technology platform provides comprehensive genomic testing services that help oncologists and pathologists select the right clinical trials and the most effective cancer therapies available for their patients, as well as monitoring patient responses, drug resistance, minimal residual disease and relapse. This includes immunotherapy, targeted therapy, combination therapy and other precision medicine approaches.
CIRCULOGENE is the only company that provides circulating DNA, RNA and MSI cancer immunotherapy testing from a single tube of blood. The laboratory’s industry-leading turnaround time ensures that complete testing results are available to physicians and their patients within one week, all from a single 4 mL tube of blood, no matter which test or how many tests are ordered.
CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited laboratory and is registered as a verified U.S. federal contractor. For more information, visit our website, connect with us on LinkedIn, Facebook and Twitter, email us at firstname.lastname@example.org or call 855-614-7083. Clinicians interested in ordering tests may visit the Contact page on CIRCULOGENE’s website.
Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. One Tube, One Week, Complete Results. Somatic + Germline; Blood + Tissue + Buccal; DNA + RNA + Immunotherapy. For more information, visit www.circulogene.com or call 855-614-7083.
About the College of American Pathologists
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the 2017 CAP Annual Report at CAP.ORG .
Copyright Business Wire 2019